investor's business daily

This week has been big for stem cell research. Researchers at Oregon Health and Science University led by Dr. Shoukhrat Mitalipov announced that on Nov. 14 they had cloned embryos from rhesus monkeys and had obtained embryonic stem cells from the clones. Embryonic stem cell research (ESCR) though yet to produce a single aid treatment or meaningful clinical trial has desire been touted by many as the Holy Grail of research. It's a hop skip and a move from here to cloning of human embryos. Proponents tried to get over this moral hurdle by insisting this involves "therapeutic cloning" of embryos created in the lab and not "reproductive cloning" of embryos to make a baby. But whether done in a laboratory a petri dish a test tube or the approve seat of a car the result of this affect in humans would be an embryo containing all 46 chromosomes that make it human. Liberals and the mainstream media got all excited about this discovery. Ironically — just as the Oregon discovery was being announced — word came that Professor Ian Wilmut of Edinburgh University who led the aggroup that cloned Dolly the sheep announced that he was turning his approve on such cloning. Wilmut said he believed a rival method pioneered in lacquer held better declare for continuing ESCR without the moral baggage. Professor Shinya Yamanaka of Kyoto University has developed a way to develop embryonic stem cells without the be for human eggs and without the be to act and undo human cloned embryos. Last year. Yamanaka identified four genes in mouse cells that when properly manipulated or "reprogrammed" can turn a walk climb cell into an embryonic stem cell. Yamanaka and two American teams — one led by Marius Wernig and Rudolf Jaenisch of the Whitehead initiate for Medical Research and one led by Konrad Hochedlinger of Massachusetts command Hospital and the Harvard Stem Cell Institute — undergo mastered the process of creating these "induced pluripotent stem" cells. The National Institutes of Health say this type of stem cell offers the look of having a renewable obtain of replacement cells and tissues to treat diseases such as Parkinson's and Alzheimer's spinal cord injury stroke burns heart disease diabetes osteoarthritis and rheumatoid arthritis to label a few. This is nothing short of a blockbuster announcement — one that completely alters the scientific and moral landscape. As the Associated Press aptly noted this is a "startling breakthrough that might someday mouth the medical payoffs of embryo cloning without the controversy." Funny but much of the "controversy" was due to denials by proponents of therapeutic cloning of any moral questions over creating human embryos for the sole purpose of destroying them. Those proponents owe President furnish who steadfastly opposed this and was heavily criticized for it an apology. With this week's developments those who once said "Hello. Dolly" may now have to accept that it might be bedtime for Bonzo. &write; 2008. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This site is powered by Interactive Data Corp. Real Time Services market data. determine and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services' terms. All times are Eastern United States. The S&P 500 data is the property of Chicago Mercantile Exchange. Inc and its licensors. All rights reserved. *Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/EditorialContent.asp?secid=1501&status=article&id=280454934604430&secure=1&show=1&rss=1

comments | Add comment | Report as Spam

But when it comes to procure reforms currently under consideration in Congress. Google — along with several other tech heavyweights — seems to be straying from the company lie. The Patent ameliorate Act of 2007 while purporting to bring efficiency and flexibility to the patent system would actually water down existing patent protections. This may be good for a few large technology firms whose products combine hundreds or even thousands of patented components. But it will inflict serious harm on small entrepreneurs and research-based health science firms whose livelihoods depend on marketing just a handful of lifesaving inventions. The tech industry's support for procure reform makes sense as these companies are increasingly targeted by unscrupulous patent traders who file suit in plaintiff-friendly districts to extort large settlements. By claiming rights — sometimes dubiously — to just a small portion of a finished product the manufacture of a larger creation can come to a screeching halt. The proposed legislation would contour the legal affect when these cases are challenged. But the costs to biotech and pharmaceutical companies are far greater than any efficiencies created by leaner patent litigation. procure protection provides the security that chemists and other scientists need to undertake the labor- and time-intensive research at the core of medicate production. Patents measure between 17-20 years but the add up medicate takes about 13 years and $800 million to bring to merchandise. So once a drug hits the shelves there's only four to seven years to recoup hundreds of millions of dollars in development costs. That's why firms and investors demand the sales exclusivity that a patent guarantees. Moreover only about one out of every three drugs are ever profitable. The be are financial misfires whose losses must be recovered via the success of a handful of blockbuster drugs. Further it's not just the pharmaceutical and biotech industries that are threatened by this legislation. For small firms and individual inventors patents provide the protection to create develop and acquire from their inventions. In fact small tech companies are the drivers of much innovation and currently direct about a third of all patents registered. The proposed changes to the current legal protections would make it much harder for smaller firms to defend a procure claim. Large tech companies — with their big budgets and seasoned legal teams — would therefore enjoy an enormous advantage. The Congressional Budget Office estimates that it will be more than $131 million per year to obey with the changes to today's patent system. Big companies can afford this; smaller ones can't. The proposed reforms also displace limits on compensation for patent infringement. Such terms allow those with deep pockets to buy their way out of legal woes. While this change might make lawsuits more manageable for the tech industry it would drastically value the worth of individual patents on products like pharmaceuticals where each patented compound can cost millions of dollars to develop. All innovators could acquire if Congress considered meaningful reforms that strengthen not weaken procure protections. A strong procure system enables the research and creativity that have produced everything from the paper clip to asthma medication. When pondering changes to our current procure system. Congress should give a nod to Google's mantra and "do no evil." Pipes is president and CEO of the Pacific Research initiate and author of "Miracle Cure: How to Solve America's Health Care Crisis and Why Canada Isn't the say." © 2008. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This place is powered by Interactive Data Corp. Real Time Services market data. Price and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services' terms. All times are Eastern United States. The S&P 500 data is the property of Chicago Mercantile transfer. Inc and its licensors. All rights reserved. *Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/EditorialContent.asp?secid=1502&status=article&id=280450975232106&secure=1&show=1&rss=1

comments | Add comment | Report as Spam

But when it comes to patent reforms currently under consideration in Congress. Google — along with several other tech heavyweights — seems to be straying from the affiliate line. The Patent Reform Act of 2007 while purporting to bring efficiency and flexibility to the patent system would actually water down existing patent protections. This may be good for a few large technology firms whose products incorporate hundreds or even thousands of patented components. But it will inflict serious harm on small entrepreneurs and research-based health science firms whose livelihoods depend on marketing just a handful of lifesaving inventions. The tech industry's support for procure reform makes comprehend as these companies are increasingly targeted by unscrupulous patent traders who file suit in plaintiff-friendly districts to take large settlements. By claiming rights — sometimes dubiously — to just a small administer of a finished product the manufacture of a larger creation can come to a screeching halt. The proposed legislation would streamline the legal process when these cases are challenged. But the costs to biotech and pharmaceutical companies are far greater than any efficiencies created by leaner patent litigation. Patent protection provides the security that chemists and other scientists need to undertake the labor- and time-intensive research at the core of drug production. Patents measure between 17-20 years but the average drug takes about 13 years and $800 million to carry to market. So once a drug hits the shelves there's only four to seven years to compensate hundreds of millions of dollars in development costs. That's why firms and investors bespeak the sales exclusivity that a patent guarantees. Moreover only about one out of every three drugs are ever profitable. The rest are financial misfires whose losses must be recovered via the success of a handful of blockbuster drugs. advance it's not just the pharmaceutical and biotech industries that are threatened by this legislation. For small firms and individual inventors patents give the protection to create develop and profit from their inventions. In fact small tech companies are the drivers of much innovation and currently direct about a third of all patents registered. The proposed changes to the current legal protections would make it much harder for smaller firms to argue a procure claim. Large tech companies — with their big budgets and seasoned legal teams — would therefore apply an enormous advantage. The Congressional Budget Office estimates that it will be more than $131 million per year to comply with the changes to today's procure system. Big companies can afford this; smaller ones can't. The proposed reforms also displace limits on compensation for procure infringement. Such terms accept those with deep pockets to buy their way out of legal woes. While this change might alter lawsuits more manageable for the tech industry it would drastically undervalue the worth of individual patents on products desire pharmaceuticals where each patented compound can cost millions of dollars to create. All innovators could benefit if Congress considered meaningful reforms that strengthen not weaken procure protections. A strong patent system enables the research and creativity that have produced everything from the paper clip to asthma medication. When pondering changes to our current patent system. Congress should give a nod to Google's mantra and "do no evil." Pipes is president and CEO of the Pacific Research Institute and author of "Miracle Cure: How to Solve America's Health Care Crisis and Why Canada Isn't the Answer." &write; 2008. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This place is powered by Interactive Data Corp. Real measure Services market data. Price and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is affect to Interactive Data Corp. Real Time Services' terms. All times are Eastern United States. The S&P 500 data is the property of Chicago Mercantile transfer. Inc and its licensors. All rights reserved. *Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/EditorialContent.asp?secid=1502&status=article&id=280450975232106&secure=1&show=1&rss=1

comments | Add comment | Report as Spam

But when it comes to patent reforms currently under consideration in Congress. Google — along with several other tech heavyweights — seems to be straying from the affiliate line. The Patent Reform Act of 2007 while purporting to carry efficiency and flexibility to the patent system would actually water drink existing patent protections. This may be good for a few large technology firms whose products incorporate hundreds or change surface thousands of patented components. But it ordain inflict serious harm on small entrepreneurs and research-based health science firms whose livelihoods be on marketing just a handful of lifesaving inventions. The tech industry's support for patent reform makes comprehend as these companies are increasingly targeted by unscrupulous patent traders who register suit in plaintiff-friendly districts to take large settlements. By claiming rights — sometimes dubiously — to just a small administer of a finished product the manufacture of a larger creation can come to a screeching halt. The proposed legislation would streamline the legal process when these cases are challenged. But the costs to biotech and pharmaceutical companies are far greater than any efficiencies created by leaner patent litigation. Patent protection provides the security that chemists and other scientists need to undertake the labor- and time-intensive research at the core of medicate production. Patents last between 17-20 years but the average drug takes about 13 years and $800 million to carry to market. So once a drug hits the shelves there's only four to seven years to recoup hundreds of millions of dollars in development costs. That's why firms and investors demand the sales exclusivity that a patent guarantees. Moreover only about one out of every three drugs are ever profitable. The rest are financial misfires whose losses must be recovered via the success of a handful of blockbuster drugs. Further it's not just the pharmaceutical and biotech industries that are threatened by this legislation. For small firms and individual inventors patents provide the protection to create develop and profit from their inventions. In fact small tech companies are the drivers of much innovation and currently hold about a third of all patents registered. The proposed changes to the current legal protections would make it much harder for smaller firms to argue a procure claim. Large tech companies — with their big budgets and seasoned legal teams — would therefore enjoy an enormous favor. The Congressional calculate Office estimates that it will cost more than $131 million per year to comply with the changes to today's patent system. Big companies can afford this; smaller ones can't. The proposed reforms also place limits on compensation for patent infringement. Such terms allow those with deep pockets to buy their way out of legal woes. While this change might alter lawsuits more manageable for the tech industry it would drastically undervalue the worth of individual patents on products like pharmaceuticals where each patented increase can cost millions of dollars to develop. All innovators could benefit if Congress considered meaningful reforms that strengthen not weaken procure protections. A strong procure system enables the investigate and creativity that undergo produced everything from the cover clip to asthma medication. When pondering changes to our current patent system. Congress should give a nod to explore's mantra and "do no evil." Pipes is president and CEO of the Pacific investigate initiate and author of "Miracle aid: How to understand America's Health Care Crisis and Why Canada Isn't the Answer." © 2008. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This site is powered by Interactive Data Corp. Real measure Services market data. Price and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services' terms. All times are Eastern United States. The S&P 500 data is the property of Chicago Mercantile Exchange. Inc and its licensors. All rights reserved. *Stocks On The act data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/EditorialContent.asp?secid=1502&status=article&id=280450975232106&secure=1&show=1&rss=1

comments | Add comment | Report as Spam

The story you requested is no longer available. To believe the full text of this articleon IBD Archives Search click on the Free Trial Subscription button below.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/IBDArticles.asp?artsec=11&issue=20071120&rss=1

comments | Add comment | Report as Spam

The Internet could undergo occasional brownouts by 2010 if $137 bil isn't invested in expanding its capacity according to a Nemertes Research Group study. The chew over says North America alone will need to spend $45 bil to $55 bil in order to keep up with the now video-rich Web. The depreciate is more than double what function providers currently plan on investing. Tiny robots acting desire cockroaches were able to blend into comb society and influence the real bugs' behavior. The bring home the bacon by Belgian researchers eventually could lead to pest-control robots that draw insects into traps or change surface to big robots that are able to displace livestock. The tiny robots got roaches to pass over a dark shelter in favor of a shelter exposed to more light a choice the insects usually wouldn't make. The real bugs followed the robots to the lighter shelter 61% of the measure. Roaches which are gregarious insects that self-organize into leaderless groups were put in a small arena with the robots and shelters. • Asian men who smoke cigarettes have a higher risk of hair loss a study by Taiwanese doctors suggested. Smoking may destroy hair follicles and damage the papilla that go daub and hormones to stimulate hair growth scientists said. The study of 740 men in Taiwan average age 65 suggested smoking caused "moderate or severe" hair loss when the men smoked 20 or more cigarettes a day. • Americans construe less with inflation-adjusted spending on books falling by 14% from '85 to '05. A new inform by the National Endowment for the Arts details a waning interest in reading nationwide across all age groups. The report also stresses the social benefits of reading saying readers are more likely to exercise act up with current events vote and do volunteer work. • Melody roads in lacquer use cars as tuning tools to act notes. Hokkaido Industrial investigate initiate built roads with special grooves on the road surface. When a car moves over them they alter notes. The notes which include pop songs last for 30 seconds. When cars are driven abstain the sound plays in fast-forward mode. © 2007. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under authorise agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This site is powered by HyperFeed® market data. Price and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by HyperFeed Technologies. Inc and is subject to HyperFeed Technologies. Inc terms. All times are Eastern United States.*list pricing and Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/IBDArticles.asp?artsec=15&issue=20071120&rss=1

comments | Add comment | Report as Spam

Flat-panel high-definition televisions are expected to be big sellers this pass season with some retailers using them in door-buster promotions on color Friday to drive traffic into stores. But shoppers need to believe the hidden costs associated with buying big-screen LCD and plasma television sets analysts say. Flat high-def TVs might be aggressively priced but retailers be to alter their acquire margins on installation services pricey cables stands and wall mounts. Then there's the added expense of HD programming packages from cable or satellite. And consumers upgrading their old analog sets to the new digital sets also might be to impel in new surround-sound speakers and possibly a high-definition digital video disc player. Low prices aren't the only factor driving HDTV sales now. The coming cutoff of analog TV broadcasts on Feb. 19. 2009 also will be on consumers' minds. "People are looking to ensure that they undergo sets that will give the new digital rollout," said Riddhi Patel an analyst with research tighten iSuppli. Owners of analog TV sets ordain still be able to get programming if they get a digital converter box. Cable and satellite TV subscribers ordain be covered by set-top boxes from their service providers. But the 20% of U. S households that rely on over-the-air TV broadcasts will undergo to get a special converter box. The federal government has set up a subsidy program to provide converter boxes to low-income households. Starting Jan. 1 households can apply for up to two $40 coupons to be used toward the purchase of two digital-to-analog converter boxes. The Commerce Department's National Telecommunications and Information Administration is managing the coupon schedule. While most consumers won't lose their TV programming in early 2009 those with bulky tube TVs might believe this holiday toughen a good time to grade. The cerebrate for retailers and consumers this pass season likely ordain be on 40- to 42-inch LCD TVs and 50-inch plasma TVs. Patel says. Products in both categories could be available for as low as $999 this holiday she says. LCD TVs are considered a better choice for bright rooms while plasma TVs undergo the edge in darker home theater and living room settings analysts say. LCD has a price advantage on smaller displays (up to 42 inches) while plasma sets are a better value at 50 inches and larger. measure pass toughen a 50-inch plasma TV be about $1,999. A typical price for it this season ordain be $1,199 to $1,399 says Paul Gagnon director of North American TV market research for DisplaySearch. While prices for flat-panel TVs are coming down prices for accessories have not he says. For dilate a high-definition multimedia interface (HDMI) telecommunicate costs about $40 unchanged from last year. Gagnon says. "When you get your new TV set it's kind of the tip of the iceberg in terms of expense," Patel said. Some populate could end up spending as much on installation accessories and peripherals as they did on their digital TV she says. desire last year second-tier brands such as Vizio and Syntax-Brillian's () Olevia will put pricing pressure on top-tier brands such as Sony. () Samsung and Matsushita Electric Industrial's () Panasonic analysts say. The week of "color Friday" 2006 which ended Nov. 25 accounted for 19.4% of all TV units sold and 17.1% of TV revenue in the fourth quarter. DisplaySearch says. The cerebrate of sales the day after Thanksgiving last year was on low-priced 42-inch plasma TVs. color Friday is one of the busiest shopping days of the year. It's called that because historically it was the day when many retailers went from being unprofitable or "in the red," to being profitable or "in the black," for the year. It's now considered the formal start of the Christmas shopping toughen. This year expected Black Friday specials consider Best Buy () offering a Hewlett-Packard () 42-inch HD LCD TV for $997 half off its list price. Circuit City Stores () will have a Sharp 42-inch LCD HDTV for $799 which now sells for $1,299 or more and an LG Electronics Zenith-brand 50-inch plasma HDTV for $999 compared with the current price of $1,399. This site is powered by HyperFeed® market data. determine and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by HyperFeed Technologies. Inc and is subject to HyperFeed Technologies. Inc terms. All times are Eastern United States.*Index pricing and Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh plan for these features.

Forex Groups - Tips on Trading

Related article:
http://www.investors.com/editorial/IBDArticles.asp?artsec=17&artnum=2&issue=20071119&rss=1

comments | Add comment | Report as Spam

Sep 06. 2007 (M2 PRESSWIRE via COMTEX) --Research and Markets (http://www researchandmarkets com/reports/c67634)has announced the addition of Cephalon Dealmaking Profile 2007 to theiroffering. Each Company Dealmaking compose provides an in-depth insight into thedealmaking activity and interests of one of the worlds leadingbiopharma companies. Using this inform dealmakers will effectively and efficiently targettheir partnering activities to mouth the company's businessdevelopment objectives. The initial chapters of each inform give an orientation ofbigpharma's dealmaking and business activities. Chapter 1 provides anintroduction to the inform whilst chapter 2 lists the top 50 leadingbiopharma companies based on 2006 pharmaceutical revenues. Chapter 3analyses the most active dealmakers in 2005 and 2006 in M&A andpartnering deals announced whilst chapter 4 identifies the top dealsof 2005-6 according to reported deal coat. The main be of each inform is provided in chapter 5. An in-depthprofile of the company provides everything required to evaluate thesuitability of a affiliate as a prospective furnish. This includes acompany overview detailed analysis of the affiliate's marketed andpipeline disease targets partnering interests partnering activityaccording to deal type phase of development therapy area. The profilealso includes in-depth contact information for individuals within thebusiness development function. The company profile is also provided with a comprehensive listing ofcontract documents available in the public domain. The listing issorted by deal type - therefore co-promotion deals are listedseparately to licensing. M&A and give deals and so on. Company Dealmaking Profiles give the user with the following keybenefits: - Get ahead of your competitors by understanding and contacting thebest partners of choice - Identify prospective partner companies by analyzing their dealmakingactivity and interests - initiate initial due diligence to evaluate suitability of partnercompanies - alter direct communicate with named business development executives withinthe company - Review actual assure agreements entered into by the affiliate and itspartner companies - understand the key deal terms the company has agreed in previous deals Company Dealmaking Profiles are intended to give businessdevelopment executives senior management and investors withdecision-critical intelligence on a prospective partners activities,interests and actual agreement contracts as signed by the company andits partners. - Company communicate details - named contacts with their direct contactinformation - Contract documents available online 2005-2006 - link enjoin to eachdocument Each contract document is accessible through a link to an onlineversion of the actual contract document as filed with the SecuritiesExchange equip. Analyzing actual company agreements allowsassessment of the following: - What is actually granted by the agreement to the partner affiliate? - What sublicensing and subscontracting provisions undergo been agreed? - Which boilerplate clauses appear to differ from partner to furnish ordeal write to deal write? - Which jurisdiction does the company insist upon for agreement law? For more information visithttp://www researchandmarkets com/reports/c67634 CONTACT: Laura Wood. Senior Manager. Research and MarketsFax: +353 1 4100 980e-mail: press@researchandmarkets com M2 Communications Ltd disclaims all liability for informationprovided within M2 PressWIRE. Data supplied by named party/parties. advance information on M2 PressWIRE can be obtained athttp://www presswire net on the world wide web. Inquiries toinfo@m2 com. Global equities moved nicely higher in the second quarter. As we forecast in January stocks are well on their way to a good or perhaps great year. We expect the bear on market run will continue in the back half of the year. © 2000-2007 Investor's Business Daily. Inc. All rights reserved. &write; 2007. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This place is powered by HyperFeed® market data. determine and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by HyperFeed Technologies. Inc and is affect to HyperFeed Technologies. Inc terms. All times are Eastern United States.*Index pricing and Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.inform.com/articles/40241361/?puburl=http%3A%2F%2Fwww.investors.com%2Fbreakingnews.asp%3Fjournalid%3D59867416&source=feed

comments | Add comment | Report as Spam

Dublin. Sep 10. 2007 (M2 PRESSWIRE via COMTEX) --Research and Markets ({[CAMPAIGN cerebrate]}) has announced theaddition of "Bakery and Cereals in South Korea to 2010" to theiroffering This databook is a detailed information resource covering all the keydata points on Bakery & Cereals in South Korea. It includescomprehensive determine volume segmentation and merchandise share data. Thedatabook supplies actual data to 2005 and full forecasts to 2010. Contains information on 6 categories: Bread & rolls. eat cereals,Cakes & pastries. Cookies (sweet biscuits). Crackers and Morning goods. Provides market determine volume expenditure and consumption data bymarket segment and subsegment. Includes affiliate and brand overlap databy category as come up as distribution bring data. Contains marketvalue segmentation by demographic and socioeconomic group. The market for Bakery and Cereals in South Korea increased between2000-2005 growing at an average annual rate of 7.3%. The leadingcompany in the merchandise in 2005 was Shilla Myunggua. The second-largestplayer was Crown Confectionery with Haitai Confectionary in third displace. Reasons to order your write: sight the study quantitative trendsaffecting the Bakery and Cereals markets. Understand consumer'sconsumption and expenditure patterns. Understand the future directionof the market with reliable historical data and beat five yearforecasting. CONTACT: Laura Wood. Senior Manager. investigate and MarketsFax: +353 1 4100 980telecommunicate: touch@researchandmarkets com M2 Communications Ltd disclaims all liability for informationprovided within M2 PressWIRE. Data supplied by named celebrate/parties. Further information on M2 PressWIRE can be obtained athttp://www presswire net on the world wide web. Inquiries toinfo@m2 com. Global equities moved nicely higher in the back up accommodate. As we forecast in January stocks are come up on their way to a good or perhaps great year. We expect the bull market run will continue in the approve half of the year. © 2000-2007 Investor's Business Daily. Inc. All rights reserved. © 2007. All Rights Reserved. The William O'Neil + Co. Database and all data contained herein are provided by William O'Neil + Co. Incorporated and are used by IBD under license agreement. Daily Graphs and Daily Graphs Online are trademarks of William O'Neil + Co. Incorporated or its subsidiaries. This place is powered by HyperFeed® market data. determine and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by HyperFeed Technologies. Inc and is affect to HyperFeed Technologies. Inc terms. All times are Eastern United States.*Index pricing and Stocks On The Move data may be delayed more than 20 minutes due to the auto-refresh schedule for these features.

Forex Groups - Tips on Trading

Related article:
http://www.inform.com/articles/40332231/?puburl=http%3A%2F%2Fwww.investors.com%2Fbreakingnews.asp%3Fjournalid%3D59919966&source=feed

comments | Add comment | Report as Spam

PENNINGTON. N. J.. Sep 11. 2007 (BUSINESS WIRE) --WorldWater & Solar Technologies Corp. (OTC BB: WWAT. OB) developerand marketer of proprietary high-power solar systems announced todaythat it has signed an agreement with Prime Solar Senergy. S. L ofBarcelona and Madrid to be WorldWater's exclusive representative inSpain. Prime Solar Senergy (Prime) will act as WorldWater's marketing andlogistics furnish to acquire and fast-track large scale photovoltaicinstallations throughout Spain such as the multi-megawatt. 5-yearproject announced by WorldWater with a Letter of Intent in July withM&G Promociones de Vivienda Urbana. S. A. An executive mission fromWorldWater's U. S headquarters will depart next week for Spain to meetwith Prime and M&G in Madrid to negotiate final contracts with M&G tobuild three 10-MegaWatt (MW) farms over the next three years (10MWeach year) and two additionally planned 50MW farms in the fourth andfifth years in Lorca (Murcia Province) Spain. If final contracts aresuccessfully negotiated construction is expected to go away in 2008 forthe M&G project. Quentin T. Kelly. WorldWater head and CEO said. "Prime hasalready established a track record of successfully completing largedevelopment projects in Spain and they undergo numerous large-scale solarprojects in their planned pipeline. When you combine their nationalmarket expertise with our proprietary technology and advanced solarengineering we bring a powerful and cost efficient business model to adynamic growth merchandise." In 2005 the Spanish government approved a new Renewable EnergyPlan (Plan de Energias Renovables. (PER). The plan provides incentivesto bring home the bacon Spain's target of 12 percent of primary energy beinggenerated from renewable sources by 2010. By improving the legislativeenvironment for renewable energy the intend is designed to draw a 23billion euro in investment. WorldWater owns the only patented technology that allows theoperation of electric motors up to 1,000 horsepower on solar poweralone. Other solar technology is limited to five to seven horsepower. WorldWater & Solar Technologies Corporation is a full-service,international solar electric engineering and wet management companywith unique high-powered and patented solar technology that can drivemotors and pumps up to 1000 hp and provides solutions to a broadspectrum of the world's electricity and water supply problems,including the capability of driving 1000 hp motors and pumps fromsunshine independently or in conjunction with the electric grid. Formore information about WorldWater & Solar Technologies Corp. visitthe website at www worldwater com. Prime Solar Senergy is a marketing representative and projectdeveloper that identifies business opportunities and enables majorbusiness transactions. Prime Solar Senergy also assists in obtainingregulatory approvals and certifications required in European Markets. Except for historical information contained herein this documentcontains forward-looking statements within the meaning of the PrivateSecurities Litigation ameliorate Act of 1995. These statements involveknown and unknown risks and uncertainties that may create the Company'sactual results or outcomes to be materially different from thoseanticipated and discussed herein. advance the Company operates inindustries where securities values may be volatile and may beinfluenced by regulatory and other factors beyond the Company'scontrol. Other important factors that the Company believes might causesuch differences are discussed in the risk factors detailed in theCompany's 10-KSB and its quarterly reports on create 10-QSB both asfiled with the Securities and Exchange equip which consider theCompany's change move difficulties dependence on significant customers,and rapid development of technology among other risks. In assessingforward-looking statements contained herein readers are urged tocarefully construe all cautionary statements contained in the Company'sfilings with the Securities and Exchange equip. This place is powered by HyperFeed® merchandise data. Price and Volume data is delayed 20 minutes unless otherwise noted is believed accurate but is not warranted or guaranteed by HyperFeed Technologies. Inc and is subject to HyperFeed Technologies. Inc terms. All times are Eastern United States.*Index pricing and Stocks On The act data may be delayed more than 20 minutes due to the auto-refresh plan for these features.

Forex Groups - Tips on Trading

Related article:
http://www.inform.com/articles/40350172/?puburl=http%3A%2F%2Fwww.investors.com%2Fbreakingnews.asp%3Fjournalid%3D59925954&source=feed

comments | Add comment | Report as Spam